The results showed that the benefit of SG over CT in PFS remained consistent across all pre-specified subgroups, including patients older than 65 years, patients with more than three prior standard therapies, including PD1/PDL1 inhibitors, patients with an initial diagnosis of TNBC, patients with metastatic disease, and other cohorts listed below. The gene discussed is CD274; the disease is metastatic neoplasm.